PEB
13/11/2014 14:00
OFFICE
REL: 1400 HRS Pacific Edge Limited
OFFICE: PEB: Pacific Edge announces appointment of CFO
13 November 2014
Pacific Edge announces appointment of Chief Financial Officer
Pacific Edge is pleased to announce the appointment of Kate Rankin as Chief
Financial Officer with effect from 17 November 2014.
Kate will join Pacific Edge from Spark New Zealand (formerly Telecom New
Zealand Limited) where she has been Senior Finance Performance Manager and
Member of the International Leadership Team.
Prior to Spark, Kate was Team Leader and Legal Entity Controller at Deutsche
Bank in London.
Commenting on the appointment, Pacific Edge Chief Executive Officer David
Darling says "We are very pleased to have someone of Kate's calibre taking up
this role. Kate will bring international business experience, finance and
leadership skills to further build the capability of the Company's senior
management team and Kate's corporate business experience in the USA, Asia and
UK will be of particular relevance as Pacific Edge looks to further
commercialise its molecular diagnostic technology including Cxbladder, in
those markets."
Kate is a member of the Chartered Accountants Australia and New Zealand and a
graduate of the University of Otago.
For more information contact:
David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800
ABOUT PACIFIC EDGE
Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic
company specialising in the discovery and commercialisation of diagnostic and
prognostic technology for the early detection and monitoring of cancer. The
company is developing and commercialising its range of Cxbladder bladder
cancer tests. It's first commercial product, Cxbladder Detect, is now being
actively marketed to physicians and clinicians in New Zealand, Australia, and
the USA through the company's wholly owned subsidiaries and selected
commercial partners.
www.pacificedge.co.nz www.pacificedgedx.com
ABOUT Cxbladder
Cxbladder Detect is a proprietary, accurate molecular diagnostic test that
enables the non-invasive detection of bladder and other urinary tract cancers
from a small volume of urine. Cxbladder Detect is commercially available in
the USA as a Laboratory Developed Test (LDT). It provides physicians and
clinicians with a quick, cost effective and accurate measure of the presence
of the cancer, and provides urologists with the opportunity to reduce their
reliance on the need for invasive tests such as cystoscopy. The Cxbladder
Detect cancer detection test has been validated by a multicentre,
international clinical study.
www.cxbladder.com
ABOUT BLADDER CANCER
Globally, bladder cancer has the 9th highest incidence and the 4th highest
incidence for men. One of the early symptoms of bladder cancer is the
presence of blood in the urine, haematuria. People with haematuria often
present to their general practitioner before being referred on to a
urologist.
Bladder cancer has a very high recurrence rate of approximately 50%-70% with
up to 30% of these recurring as later stage tumours. However, bladder cancers
are highly treatable, especially if detected in the early stages when there
is a much higher probability of survival for early stage tumours relative to
later stage tumours. This makes timely and regular surveillance and
monitoring of this cancer a key element of the clinical process and of the
individual's annual healthcare plan.
End CA:00257620 For:PEB Type:OFFICE Time:2014-11-13 14:00:11
